Available clinical trials

Brain

  • 14058: Ph II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Vs Conventional Photon Irradiation with Concomitant and Adj Temozolomide in Pts w/ Newly Diagnosed Glioblastoma
    Click here for more information

Breast

  • 13091: A Randomized Phase III Clinical Trial Evaluating Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
    Click here for more information

Colorectal

  • 15240: A single arm, open-label, multicenter, multinational, safety and efficacy Phase IIIb trial of BI 695502 plus mFOLFOX6 in patients with previously untreated metastatic colorectal cancer (1302.3)
    Click here for more information

Gastric

  • 16164: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (CheckMate 649: CHECKpoint pathway and nivoluMab Clinical Trial Evaluation 649)
    Click here for more information

Head & Neck

  • 16204: A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412)
    Click here for more information
  • 10025: A phase III study of postoperative radiation therapy (IMRT) +/- cetuximab for locally-advanced resected head and neck cancer (RTOG 0920)
    Click here for more information

Hematologic and Leukemia

  • 15229: (UTX-TGR-304) Ph 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Comb. with TGR-1202 Compared to Obinutuzumab in Comb. with Chlorambucil in Patients with CLL
    Click here for more information
  • 15223: A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204)
    Click here for more information
  • 15222: A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy (ACE-CL-208)
    Click here for more information
  • 15005: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M)
    Click here for more information

Lung

  • 16156: CA209-817: A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer
    Click here for more information
  • 14158: CA209370: A Master Protocol of Ph 1/2 Studies of Nivolumab in Adv NSCLC Using Nivolumab as Maintenance after Induction Chemo or as First-line Trtmnt Alone or in Combo w/ SOC Therapies.
    Click here for more information

Lymphoma

  • 16100: Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices (CA209655)
    Click here for more information
  • 15054: BO29563 - A PHASE IB/II STUDY EVALUATING THE SAFETY AND EFFICACY OF MPDL3280A IN COMB. WITH EITHER OBINUTUZUMAB + BENDAMUSTINE OR OBINUTUZUMAB + CHOP IN PTS WITH FOLLICULAR LYMPHOMA OR DLBCL.
    Click here for more information
  • 15053: PHASE I/IB DOSE ESCALATION STUDY EVALUATING THE PHARMACOKINETICS, SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF DCDS0780A, ALONE OR IN COMBINATION WITH RITUXIMAB, IN PTS WITH R/R B-CELL NHL
    Click here for more information
  • 13064: Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or MCL (CC-5013-NHL-008)
    Click here for more information
  • 11282: A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)
    Click here for more information

Myelomas

  • 16084: Daratumumab plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD)in Previously Untreated and Relapsed Subjects with Multiple Myeloma (54767414MMY2012)
    Click here for more information
  • 15143: A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM). (KEYNOTE 183)
    Click here for more information
  • 15137: A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185)
    Click here for more information

Ovarian

  • 16211: PR-30-5017-C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy (PRIMA)
    Click here for more information
  • 16081: FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician’s Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects with Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (OX4325)
    Click here for more information
  • 16080: A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMB. WITH AND/OR FOLLOWING CHEMO IN PTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER (B9991010)
    Click here for more information
  • 16043: A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
    Click here for more information

Prostate

  • 16159: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESISINHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN - Roche CO39385

    Click here for more information

Solid Tumors

  • 16041: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)
    Click here for more information
  • 15026: Efficacy and Safety of Rivaroxaban Prophylaxis Compared w/ Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism (39039039STM4001)
    Click here for more information

Urothelial

  • 16054: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemo vs Chemo in Subjects with Adv. or Metastatic Urothelial CA (MK-3475-361)
    Click here for more information